Global Patent Index - EP 2950796 A1

EP 2950796 A1 20151209 - PHARMACEUTICAL COMPOSITION COMPRISING LEFLUNOMIDE

Title (en)

PHARMACEUTICAL COMPOSITION COMPRISING LEFLUNOMIDE

Title (de)

PHARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND LEFLUNOMID

Title (fr)

COMPOSITION PHARMACEUTIQUE CONTENANT DU LÉFLUNOMIDE

Publication

EP 2950796 A1 20151209 (DE)

Application

EP 14700203 A 20140106

Priority

  • DE 102013001636 A 20130131
  • DE 102013007106 A 20130425
  • EP 2014000006 W 20140106

Abstract (en)

[origin: WO2014096464A1] The present invention relates to a pharmaceutical composition according to the invention containing 14 to 17.5 mg leflunomide prepared as a single dose and uses thereof.

IPC 8 full level

A61K 31/42 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01)

CPC (source: EP)

A61K 31/42 (2013.01); A61P 29/00 (2017.12); A61P 37/06 (2017.12)

Citation (search report)

See references of WO 2014096464A1

Citation (examination)

  • SMOLEN JOSEF S ET AL: "The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy", JOURNAL OF RHEUMATOLOGY, JOURNAL OF RHEUMATOLOGY PUBLISHING CO. LTD, CA, vol. 71, no. SUPPLEMENT, 31 May 2004 (2004-05-31), pages 13 - 20, XP009501839, ISSN: 0380-0903
  • ANONYMOUS: "Assessment report Leflunomide medac", 30 May 2013 (2013-05-30), pages 1 - 26, XP055507770, Retrieved from the Internet <URL:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001227/WC500151737.pdf> [retrieved on 20180918]

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2014096464 A1 20140626; CA 2899746 A1 20140626; EP 2950796 A1 20151209

DOCDB simple family (application)

EP 2014000006 W 20140106; CA 2899746 A 20140106; EP 14700203 A 20140106